IRVINE, Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the "Company"), announced
today that its second quarter 2017 financial results will be released
after the market closes on Tuesday, August 1, 2017. Following the
release, the Company will host a live conference call and webcast at
5:00 p.m. Eastern Time to discuss the Company's financial results and
provide a general business update.
The live webcast and a replay may be accessed by visiting the Company's
website at http://investors.aeriepharma.com.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call (888)
734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live
conference call. The conference ID number for the live call is 51660946.
Please dial in approximately 10 minutes prior to the call. Telephone
replay will be available approximately two hours after the call. To
access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is 51660946.
The telephone replay will be available until August 8, 2017.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two current product candidates are once-daily intraocular
pressure lowering therapies with novel mechanisms of action to treat
patients with glaucoma or ocular hypertension. The NDA (new drug
application) for RhopressaTM (netarsudil ophthalmic solution)
0.02% was submitted to the U.S. Food and Drug Administration (FDA) in
February 2017, and, in May 2017, the FDA set the PDUFA (Prescription
Drug User Fee Act) goal date for the completion of the FDA's review of
the RhopressaTM NDA for February 28, 2018. Aerie's second
product candidate, RoclatanTM (netarsudil/latanoprost
ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of
RhopressaTM and widely prescribed PGA latanoprost, achieved
its primary efficacy endpoint in two Phase 3 registration trials, named
Mercury 1 and Mercury 2, and also achieved successful 12-month safety
and efficacy results in Mercury 1. The RoclatanTM NDA
submission is expected to take place in the first half of 2018. Aerie is
also focused on the development of additional product candidates and
technologies in ophthalmology.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170726005007/en/
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals
Source: Aerie Pharmaceuticals, Inc.
News Provided by Acquire Media